A Study of Napabucasin Plus Nab-Paclitaxel With Gemcitabine in Adult Patients With Metastatic Pancreatic Adenocarcinoma

Official Title

A Phase III Study of BBI-608 Plus Nab-Paclitaxel With Gemcitabine in Adult Patients With Metastatic Pancreatic Adenocarcinoma

Summary:

This is a randomized, open-label, multi-centre, phase 3 study of napabucasin plus weekly nab-paclitaxel with gemcitabine versus weekly nab-paclitaxel with gemcitabine for adult patients with Metastatic Pancreatic Ductal Adenocarcinoma.

Trial Description

Primary Outcome:

  • Overall Survival
Secondary Outcome:
  • Overall Survival in biomarker positive patients
  • Progression Free Survival
  • Progression Free Survival in biomarker positive patients
  • Overall Response Rate
  • Disease Control Rate
  • Overall Response Rate in biomarker positive patients
  • Disease Control Rate in biomarker positive patients
  • Quality of Life (QoL)
  • Number of Patients with Adverse Events

View this trial on ClinicalTrials.gov

Interested in this trial?

Print this page and take it to your doctor to discuss your eligibilty and treatment options. Only your doctor can refer you to a clinical trial.

Resources

Canadian Cancer Society

These resources are provided in partnership with the Canadian Cancer Society